Product: Phospho-SHC (Ser36) Antibody
Catalog: AF8232
Description: Rabbit polyclonal antibody to Phospho-SHC (Ser36)
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Prediction: Horse, Dog
Mol.Wt.: 70kDa; 63kD(Calculated).
Uniprot: P29353
RRID: AB_2840294

View similar products>>

   Size Price Inventory
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Horse(91%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Phospho-SHC (Ser36) Antibody detects endogenous levels of SHC only when phosphorylated at Ser36.
RRID:
AB_2840294
Cite Format: Affinity Biosciences Cat# AF8232, RRID:AB_2840294.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

FLJ26504; p66; p66SHC; SH2 domain protein C1; SHC (Src homology 2 domain containing) transforming protein 1; SHC 1; SHC A; SHC adaptor protein 1; Shc; SHC transforming protein 1; SHC transforming protein; SHC-transforming protein 1; SHC-transforming protein 3; SHC-transforming protein A; SHC1; SHC1_HUMAN; SHCA; Src homology 2 domain-containing-transforming protein C1;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P29353 SHC1_HUMAN:

Widely expressed. Expressed in neural stem cells but absent in mature neurons.

Sequence:
MDLLPPKPKYNPLRNESLSSLEEGASGSTPPEELPSPSASSLGPILPPLPGDDSPTTLCSFFPRMSNLRLANPAGGRPGSKGEPGRAADDGEGIVGAAMPDSGPLPLLQDMNKLSGGGGRRTRVEGGQLGGEEWTRHGSFVNKPTRGWLHPNDKVMGPGVSYLVRYMGCVEVLQSMRALDFNTRTQVTREAISLVCEAVPGAKGATRRRKPCSRPLSSILGRSNLKFAGMPITLTVSTSSLNLMAADCKQIIANHHMQSISFASGGDPDTAEYVAYVAKDPVNQRACHILECPEGLAQDVISTIGQAFELRFKQYLRNPPKLVTPHDRMAGFDGSAWDEEEEEPPDHQYYNDFPGKEPPLGGVVDMRLREGAAPGAARPTAPNAQTPSHLGATLPVGQPVGGDPEVRKQMPPPPPCPGRELFDDPSYVNVQNLDKARQAVGGAGPPNPAINGSAPRDLFDMKPFEDALRVPPPPQSVSMAEQLRGEPWFHGKLSRREAEALLQLNGDFLVRESTTTPGQYVLTGLQSGQPKHLLLVDPEGVVRTKDHRFESVSHLISYHMDNHLPIISAGSELCLQQPVERKL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
100
Horse
91
Zebrafish
67
Pig
0
Bovine
0
Sheep
0
Xenopus
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P29353 As Substrate

Site PTM Type Enzyme
Phosphorylation
M1 Acetylation
S28 Phosphorylation Q05655 (PRKCD)
S36 Phosphorylation P45984 (MAPK9) , P53779 (MAPK10) , P05771 (PRKCB) , Q16539 (MAPK14) , P27361 (MAPK3) , P45983 (MAPK8)
S54 Phosphorylation Q16539 (MAPK14)
T56 Phosphorylation Q16539 (MAPK14)
S115 Phosphorylation
S139 Phosphorylation Q05655 (PRKCD)
K143 Ubiquitination
T145 Phosphorylation
K154 Ubiquitination
Y162 Phosphorylation
K203 Ubiquitination
T206 Phosphorylation
S213 Phosphorylation
K226 Ubiquitination
K313 Ubiquitination
Y315 Phosphorylation Q05397 (PTK2)
K321 Ubiquitination
T324 Phosphorylation
S335 Phosphorylation
Y349 Phosphorylation P12931 (SRC) , P06241 (FYN) , P35916 (FLT4) , P43405 (SYK) , P43403 (ZAP70) , P36888 (FLT3)
Y350 Phosphorylation P12931 (SRC) , P06241 (FYN) , P35916 (FLT4) , P36888 (FLT3) , P43405 (SYK) , P43403 (ZAP70)
T386 Phosphorylation Q16539 (MAPK14)
S426 Phosphorylation
Y427 Phosphorylation P43403 (ZAP70) , P08581 (MET) , P06239 (LCK) , P36888 (FLT3) , P35916 (FLT4) , P06241 (FYN) , P12931 (SRC) , P43405 (SYK)
K435 Ubiquitination
S453 Phosphorylation
K462 Ubiquitination
S494 Phosphorylation
S513 Phosphorylation
Y520 Phosphorylation

PTMs - P29353 As Enzyme

Substrate Site Source
P43403-2 (ZAP70) Y167 Uniprot

Research Backgrounds

Function:

Signaling adapter that couples activated growth factor receptors to signaling pathways. Participates in a signaling cascade initiated by activated KIT and KITLG/SCF. Isoform p46Shc and isoform p52Shc, once phosphorylated, couple activated receptor tyrosine kinases to Ras via the recruitment of the GRB2/SOS complex and are implicated in the cytoplasmic propagation of mitogenic signals. Isoform p46Shc and isoform p52Shc may thus function as initiators of the Ras signaling cascade in various non-neuronal systems. Isoform p66Shc does not mediate Ras activation, but is involved in signal transduction pathways that regulate the cellular response to oxidative stress and life span. Isoform p66Shc acts as a downstream target of the tumor suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. The expression of isoform p66Shc has been correlated with life span (By similarity). Participates in signaling downstream of the angiopoietin receptor TEK/TIE2, and plays a role in the regulation of endothelial cell migration and sprouting angiogenesis.

PTMs:

Phosphorylated by activated epidermal growth factor receptor. Phosphorylated in response to FLT4 and KIT signaling. Isoform p46Shc and isoform p52Shc are phosphorylated on tyrosine residues of the Pro-rich domain. Isoform p66Shc is phosphorylated on Ser-36 by PRKCB upon treatment with insulin, hydrogen peroxide or irradiation with ultraviolet light (By similarity). Tyrosine phosphorylated in response to FLT3 signaling (By similarity). Tyrosine phosphorylated by activated PTK2B/PYK2 (By similarity). Tyrosine phosphorylated by ligand-activated ALK. Tyrosine phosphorylated by ligand-activated PDGFRB. Tyrosine phosphorylated by TEK/TIE2. May be tyrosine phosphorylated by activated PTK2/FAK1; tyrosine phosphorylation was seen in an astrocytoma biopsy, where PTK2/FAK1 kinase activity is high, but not in normal brain tissue. Isoform p52Shc dephosphorylation by PTPN2 may regulate interaction with GRB2.

Subcellular Location:

Cytoplasm.

Mitochondrion matrix.
Note: Localized to the mitochondria matrix. Targeting of isoform p46Shc to mitochondria is mediated by its first 32 amino acids, which behave as a bona fide mitochondrial targeting sequence. Isoform p52Shc and isoform p66Shc, that contain the same sequence but more internally located, display a different subcellular localization.

Mitochondrion.
Note: In case of oxidative conditions, phosphorylation at 'Ser-36' of isoform p66Shc, leads to mitochondrial accumulation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed. Expressed in neural stem cells but absent in mature neurons.

Subunit Structure:

Interacts with CPNE3; this interaction may mediate the binding of CPNE3 with ERBB2. Interacts with the NPXY motif of tyrosine-phosphorylated IGF1R and INSR in vitro via the PID domain. Once activated, binds to GRB2. Interacts with tyrosine-phosphorylated CD3T and DDR2. Interacts with the N-terminal region of APS. Interacts with phosphorylated LRP1 and IRS4. Interacts with INPP5D/SHIP1 and INPPL1/SHIP2. Interacts with TRIM31. Interacts with PTPN6/SHP (tyrosine phosphorylated). Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTT (By similarity). Interacts with ALK, GAB2, GRB7 and KIT. Interacts with FLT4 (tyrosine-phosphorylated). Interacts with EPHB1 and GRB2; activates the MAPK/ERK cascade to regulate cell migration. Interacts with PDGFRB (tyrosine-phosphorylated). Interacts with ERBB4. Interacts with TEK/TIE2 (tyrosine-phosphorylated). Interacts with the Trk receptors NTRK1, NTRK2 and NTRK3; in a phosphotyrosine-dependent manner. Interacts with PTK2/FAK1. Interacts with CEACAM1; this interaction is CEACAM1-phosphorylation-dependent and mediates interaction with EGFR or INSR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Interacts (via PID domain) with PEAK1 (when phosphorylated at 'Tyr-1188'). Found in a complex with PPP1CA, PPP1CC, SHC1 and PEAK1.

(Microbial infection) Interacts with herpes simplex virus 1 UL46.

Family&Domains:

In response to a variety of growth factors, isoform p46Shc and isoform p52Shc bind to phosphorylated Trk receptors through their phosphotyrosine binding (PID) and/or SH2 domains. The PID and SH2 domains bind to specific phosphorylated tyrosine residues in the Asn-Pro-Xaa-Tyr(P) motif of the Trk receptors. Isoform p46Shc and isoform p52Shc are in turn phosphorylated on three tyrosine residues within the extended proline-rich domain. These phosphotyrosines act as docking site for GRB2 and thereby are involved in Ras activation (By similarity).

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). VDR alleviates endothelial cell injury in arteriovenous fistula through inhibition of P66Shc-mediated mitochondrial ROS. Scientific reports, 2023 (PubMed: 37422508) [IF=4.6]

Application: WB    Species: Human    Sample:

Figure 2 The expression of VDR, P66Shc, P-P66Shc and oxidative stress, fibrosis paramaters in AVF stenosis vessels. (A) IHC staining of VDR (left panels, magnification 20 × , right panel, magnification 400 ×) in the AVF stenosis patients and control subjects. (B) IHC staining of P66Shc (left panel), P-P66Shc (middle panel) and oxidative stress parameter, 8-ohdG (right panel) of two groups. (C) Western blot analysis of FN (upper panel), Col-1, P66Shc, P-P66Shc(middle panel) and VDR (bottom panel) protein expression in AVF vascular tissue of two groups . (D) Semiquantitative analysis of IHC stained with 8-ohdG, *P 

Application: IHC    Species: Human    Sample:

Figure 2 The expression of VDR, P66Shc, P-P66Shc and oxidative stress, fibrosis paramaters in AVF stenosis vessels. (A) IHC staining of VDR (left panels, magnification 20 × , right panel, magnification 400 ×) in the AVF stenosis patients and control subjects. (B) IHC staining of P66Shc (left panel), P-P66Shc (middle panel) and oxidative stress parameter, 8-ohdG (right panel) of two groups. (C) Western blot analysis of FN (upper panel), Col-1, P66Shc, P-P66Shc(middle panel) and VDR (bottom panel) protein expression in AVF vascular tissue of two groups . (D) Semiquantitative analysis of IHC stained with 8-ohdG, *P 

2). Mitochondrial Translocation of P66Shc Aggravates Cisplatin-induced AKI by Promoting Ferroptosis. Current medicinal chemistry, 2023 (PubMed: 35986536) [IF=4.1]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.